AT3185U2 - Paroxetinmethansulfonat - Google Patents

Paroxetinmethansulfonat Download PDF

Info

Publication number
AT3185U2
AT3185U2 AT0027999U AT27999U AT3185U2 AT 3185 U2 AT3185 U2 AT 3185U2 AT 0027999 U AT0027999 U AT 0027999U AT 27999 U AT27999 U AT 27999U AT 3185 U2 AT3185 U2 AT 3185U2
Authority
AT
Austria
Prior art keywords
composition
carrier comprises
composition according
medicament
carrier
Prior art date
Application number
AT0027999U
Other languages
English (en)
Other versions
AT3185U3 (de
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT3185(U2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AT3185U2 publication Critical patent/AT3185U2/de
Publication of AT3185U3 publication Critical patent/AT3185U3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Piperidinverbindungen (Paroxetinmethansulfonat), Verfahren zu ihrer Herstellung, Arzneimittel, die sie umfassen, und ihre therapeutische Verwendung werden offenbart.

Claims (20)

  1. AT 003 185 U2 ANSPRÜCHE 1. Paroxetinmethansulfonat das unter anderem die folgenden charakteristischen IR-Si-gnale aufweist: 1603, 1513,1194,1045, 946, 830,776, 601, 554 und 539 ± 4 cm'1 und/oder die folgenden charakteristischen Röntgendiffraktometrie (XRD)-Signale. 8,3, 10,5, 15,6, 16,3,17,7,18,2,19,8,20,4,21,5,22,0,22,4,23,8,24,4,25,0, 25,3,25,8,26,6, 30,0,30,2 und 31,6± 0,2 °2Θ.
  2. 2. Arzneimittel, umfassend eine Verbindung nach Anspruch 1 und einen pharmazeutisch verträglichen Träger.
  3. 3. Zusammensetzung nach Anspruch 2, wobei der Träger ein Sprengmittel umfasst.
  4. 4. Zusammensetzung nach Anspruch 2 oder 3, wobei der Träger ein Bindemittel umfasst.
  5. 5. Zusammensetzung nach einem der Ansprüche 2 bis 4, wobei der Träger ein farbgebendes Mittel umfasst.
  6. 6. Zusammensetzung nach einem der Ansprüche 2 bis 5, wobei der Träger einen Geschmacksstoff umfasst.
  7. 7. Zusammensetzung nach einem der Ansprüche 2 bis 6, wobei der Träger ein Konservierungsmittel umfasst.
  8. 8. Zusammensetzung nach einem der Ansprüche 2 bis 7, das der oralen Verabreichung angepasst ist.
  9. 9. Zusammensetzung nach Anspruch 8, das eine Tablette oder Kapsel ist.
  10. 10. Zusammensetzung nach einem der Ansprüche 2 bis 9, umfassend 1 bis 200 mg des Wirkstoffes, berechnet auf der Grundlage der freien Base.
  11. 11. Verwendung einer Verbindung gemäß Anspruch 1 zur Herstellung eines Arzneimittels zur Verwendung bei der Behandlung und/oder Vorbeugung einer beliebigen oder mehrerer der Erkrankungen. 40 AT 003185 U2
  12. 12. Arzneimittel umfassend 1 bis 200 mg Paroxetinmethansulfonat, berechnet auf der Grundlage der freien Base, und einen pharmazeutisch verträglichen Träger.
  13. 13. Zusammensetzung nach Anspruch 12, wobei der Träger ein Sprengmittel umfasst.
  14. 14. Zusammensetzung nach Anspruch 12 oder 13, wobei der Träger ein Bindemittel umfasst.
  15. 15. Zusammensetzung nach einem der Ansprüche 12 bis 14, wobei der Träger ein farbgebendes Mittel umfasst.
  16. 16. Zusammensetzung nach einem der Ansprüche 12 bis 15, wobei der Träger einen GeschmacksstofF umfasst.
  17. 17. Zusammensetzung nach einem der Ansprüche 12 bis 16, wobei der Träger ein Konservierungsmittel umfasst.
  18. 18. Zusammensetzung nach einem der Ansprüche 12 bis 17, die der oralen Verabreichung angepasst ist.
  19. 19. Zusammensetzung nach Anspruch IS, die eine Tablette oder Kapsel ist.
  20. 20. Verwendung von Paroxetinmethansulfonat zur Herstellung eines Arzneimittels zur Verwendung bei der Behandlung und/oder Vorbeugung einer oder mehrerer Erkrankungen, ausgewählt aus Alkoholismus, Trichotillomanie, Substanzenmißbrauch, Angstzuständen, chronischen Schmerzen, Depressionen im Jugendalter und Dysthymie. 41
AT0027999U 1998-07-02 1999-04-23 Paroxetinmethansulfonat AT3185U3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (2)

Publication Number Publication Date
AT3185U2 true AT3185U2 (de) 1999-11-25
AT3185U3 AT3185U3 (de) 2000-01-25

Family

ID=27269380

Family Applications (4)

Application Number Title Priority Date Filing Date
AT99918159T ATE251155T1 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat-acetonitrilsolvat 1:1
AT99303151T ATE195121T1 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat
AT0027999U AT3185U3 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat
AT00201290T ATE202777T1 (de) 1998-07-02 2000-04-10 Paroxetinmethansulfonat

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99918159T ATE251155T1 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat-acetonitrilsolvat 1:1
AT99303151T ATE195121T1 (de) 1998-07-02 1999-04-23 Paroxetinmethansulfonat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00201290T ATE202777T1 (de) 1998-07-02 2000-04-10 Paroxetinmethansulfonat

Country Status (34)

Country Link
US (4) US6063927A (de)
EP (5) EP0970955B1 (de)
JP (1) JP2002519422A (de)
KR (1) KR20010053336A (de)
CN (1) CN1127502C (de)
AR (2) AR011759A1 (de)
AT (4) ATE251155T1 (de)
AU (4) AU3619199A (de)
BE (3) BE1012403A5 (de)
BR (1) BR9911682A (de)
CA (1) CA2269999A1 (de)
CH (1) CH689805A8 (de)
DE (5) DE29907248U1 (de)
DK (7) DK199900176U3 (de)
ES (4) ES2209428T3 (de)
FI (2) FI4209U1 (de)
FR (2) FR2780728B1 (de)
GB (5) GB2377637A (de)
GR (3) GR990100140A (de)
HU (1) HUP0102334A3 (de)
IE (5) IES81166B2 (de)
IL (1) IL140628A (de)
IT (1) IT1312540B1 (de)
LU (1) LU90388B1 (de)
NL (4) NL1011875C2 (de)
NO (1) NO319030B1 (de)
NZ (1) NZ509180A (de)
PL (1) PL345214A1 (de)
PT (4) PT1020464E (de)
SE (1) SE9901462A0 (de)
SI (3) SI0970955T1 (de)
SK (1) SK20262000A3 (de)
TR (1) TR200100054T2 (de)
WO (1) WO2000001694A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
BR9807625A (pt) * 1997-02-27 2000-02-22 Ajinomoto Kk Aparelho e processo para cristalização.
JP2002503248A (ja) * 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ ４−フェニルピペリジン化合物
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP1313474A2 (de) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetin-zusammensetzungen und verfahren zu deren herstellung
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1874908B1 (de) * 2005-04-07 2014-06-11 Xy, Llc Methode zur Reduktion von Mikroorganismen in einem Durchflussweg unter Verwendung von Diacetonalkohol
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20100093749A1 (en) * 2007-03-09 2010-04-15 Novartis Ag Compounds
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (de) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223430B1 (de) * 1985-10-21 1991-02-27 Honda Giken Kogyo Kabushiki Kaisha Methode zur Steuerung des Spulenstroms eines Magnetventils, das die Saufluftmenge eines Innenverbrennungsmotors steuert
EP0223403B1 (de) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
EP0269383A3 (de) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated Verwendbarkeit von 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanolen als Antiallergiker
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
EP0818990A1 (de) * 1995-04-03 1998-01-21 Abbott Laboratories Homogene mischungen aus niedrigschmelzenden arzneistoffen und additiven zur verzögerten wirkstoffeingabe
CA2220963A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (de) * 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
JP2002503248A (ja) * 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ ４−フェニルピペリジン化合物
EP1053234A1 (de) * 1998-02-06 2000-11-22 Smithkline Beecham Plc Salze von paroxetin
CA2323896A1 (en) * 1998-03-16 1999-09-23 Andrew Simon Craig Crystalline form of paroxetine
SK15032000A3 (sk) * 1998-04-09 2001-04-09 Smithkline Beecham Plc Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
FI112077B (fi) 2003-10-31
SK20262000A3 (sk) 2001-07-10
BE1012403A5 (fr) 2000-10-03
US6063927A (en) 2000-05-16
AU713131B3 (en) 1999-11-25
DK199900554A (da) 2000-01-03
PT970955E (pt) 2000-11-30
FR2780728A1 (fr) 2000-01-07
NL1011875C2 (nl) 2000-03-24
ITMI990866A1 (it) 2000-10-23
GB2352395B (en) 2004-02-11
NO991944L (no) 2000-01-03
EP1089996B1 (de) 2003-10-01
BE1011664A6 (fr) 1999-11-09
DE69900007D1 (de) 2000-09-07
IES20000894A2 (en) 2001-05-30
DE69911774T2 (de) 2004-08-05
IL140628A (en) 2004-06-20
GB9909505D0 (en) 1999-06-23
SI1020464T1 (en) 2001-12-31
AT3185U3 (de) 2000-01-25
GR1003350B (el) 2000-03-29
FIU990190U0 (fi) 1999-04-23
IES20000893A2 (en) 2001-05-30
GB2377637A (en) 2003-01-22
EP0970955B1 (de) 2000-08-02
IES990343A2 (en) 2000-01-02
DE60000003D1 (de) 2001-08-09
ATE202777T1 (de) 2001-07-15
JP2002519422A (ja) 2002-07-02
US20010023253A1 (en) 2001-09-20
DE60000003T2 (de) 2002-03-21
GB2367003A (en) 2002-03-27
SE9901462L (de)
DE29907248U1 (de) 1999-09-09
BE1012420A6 (fr) 2000-10-03
PT102291A (pt) 2000-05-31
FI990922A0 (fi) 1999-04-23
WO2000001694A1 (en) 2000-01-13
HK1037877A1 (en) 2002-02-22
CH689805A5 (fr) 1999-11-30
KR20010053336A (ko) 2001-06-25
NO319030B1 (no) 2005-06-06
FI4209U1 (fi) 1999-11-10
DK200000390U1 (da) 2000-12-27
LU90388B1 (fr) 2001-01-29
EP1089996A1 (de) 2001-04-11
ES2157881T3 (es) 2001-09-01
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
IE20000633A1 (en) 2001-10-17
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
GR990100140A (el) 2000-03-31
AR011759A1 (es) 2000-09-13
FR2780728B1 (fr) 2001-02-16
DK199900234U4 (da) 2000-12-22
NL1012271C2 (nl) 1999-09-23
AU732211C (en) 2004-05-06
CN1315949A (zh) 2001-10-03
FR2802098A1 (fr) 2001-06-15
DK199900176U3 (da) 1999-08-13
EP0970955A1 (de) 2000-01-12
NZ509180A (en) 2001-06-29
IES81166B2 (en) 2000-05-31
ES2149044T3 (es) 2000-10-16
US20020035130A1 (en) 2002-03-21
PT1020464E (pt) 2001-10-30
AR018197A1 (es) 2001-10-31
DE69911774D1 (de) 2003-11-06
GB2352395A (en) 2001-01-31
GB0026487D0 (en) 2000-12-13
AU732211B2 (en) 2001-04-12
EP1020464A1 (de) 2000-07-19
CN1127502C (zh) 2003-11-12
AU2392899A (en) 2000-01-20
AU713877B3 (en) 1999-12-09
AU3619199A (en) 2000-01-24
GB2339428A (en) 2000-01-26
ATE195121T1 (de) 2000-08-15
BR9911682A (pt) 2001-12-26
IT1312540B1 (it) 2002-04-22
ES2209428T3 (es) 2004-06-16
ATE251155T1 (de) 2003-10-15
EP1020464B1 (de) 2001-07-04
DK1020464T3 (da) 2001-09-24
NO991944D0 (no) 1999-04-23
GB2336364B (en) 2000-05-10
NL1012272C1 (nl) 1999-07-12
NL1011874C1 (nl) 1999-07-12
GR3034328T3 (en) 2000-12-29
DK199900234U1 (da) 2000-12-22
IL140628A0 (en) 2002-02-10
SI0970955T1 (en) 2001-02-28
FI990922L (fi) 2000-01-03
HUP0102334A2 (hu) 2002-05-29
CH689805A8 (fr) 2000-02-29
NL1011875A1 (nl) 2000-01-07
GB9920332D0 (en) 1999-11-03
US20020193406A1 (en) 2002-12-19
ES2158778A1 (es) 2001-09-01
SE9901462A0 (sv) 2000-01-03
HUP0102334A3 (en) 2003-12-29
DK1089996T3 (da) 2004-02-09
DE69900007T2 (de) 2001-06-07
DE19918588A1 (de) 2000-01-27
ES2158778B1 (es) 2002-03-16
GB2336364A (en) 1999-10-20
CA2269999A1 (en) 2000-01-02
GR3036208T3 (en) 2001-10-31
SI1089996T1 (en) 2004-04-30
DK0970955T3 (da) 2000-10-09
TR200100054T2 (tr) 2001-06-21
EP1020463A1 (de) 2000-07-19
PL345214A1 (en) 2001-12-03
EP1288214A1 (de) 2003-03-05
IE990344A1 (en) 2000-05-03
SE9901462D0 (sv) 1999-04-23
PT102291B (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
DE60103556T3 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
DE60219478T2 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
DE60016602T2 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
AT403988B (de) Festes orales retardpräparat
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
AU2011365756B2 (en) Antihypertensive pharmaceutical composition
DE60122015T2 (de) Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
HK1042303A1 (zh) 新的化合物
DE69909209T2 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
CA2005980A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
DE60216776T2 (de) Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen
WO2000066550A8 (en) New compounds
WO2000048599A1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69905034T2 (de) Stabile zusammensetzungen enthaltend levosimendan und alginsäure
DE2756802A1 (de) Pharmazeutische mischung
DE69625210T2 (de) Nicorandil gegen angstneurosen
DE102005060377A1 (de) Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
DE69903546T2 (de) Levosimendan für die behandlung von pulmonaler hypertonie
GB2244431A (en) Treatment of age related memory impairment and other cognitive disorders
DE60019591T2 (de) Behandlung oder hemmung von koronarimplantat vasospasm
EP0301373B1 (de) Erzeugnisse, enthaltend Gallopamil und Prazosin
DE3005029C2 (de) Antihypertensive pharmazeutische Zubereitungen
AT393960B (de) Verfahren zur kombination eines beta-adrenorezeptorblockers und eines diuretikums

Legal Events

Date Code Title Description
PW9K Partial renouncement
MN9K Cancelled due to lapse of time